Predicting Treatment Response in Psychiatric Disorders Using Biological Markers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study explores links between inflammation and treatment resistance across psychiatric disorders such as schizophrenia, TRD, bipolar disorder, catatonia, and OCD. It uses biological samples (blood, CSF via lumbar puncture, stool, and skin microbiopsy) alongside psychometric scales to identify markers that may predict treatment response. The goal is to understand how immune and inflammatory processes relate to how patients respond to therapies. The trial is conducted at centers in Paris, led by Centre Hospitalier St Anne with Collaboration from GHU Paris Psychiatry & Neurosciences. Participants include adults starting a new treatment and meeting DSM-5 criteria for a psychiatric disorder, with appropriate safety and consent procedures in place.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged ≥ 18 years old;
* Patient suffering from a psychiatric disorder according to DSM-5 criteria;
* Patient with drug-resistant disease according to the definition of the protocol
* Patient starting a new treatment for his pathology;
* Patient informed and having signed an informed consent;
* Patient covered by the social security system.

Exclusion Criteria:

* Patient with major neurocognitive disorder diagnosed (dementia syndrome)
* Pregnant, laboring, or breastfeeding female patients
* Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included.
* For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.

Where it's running

• GHU Paris - Psychiatrie et Neurosciences
  Paris, France Recruiting

Study contacts

• Study coordinator: Iolanda PALIMARU, MD
• Email: iolanda.palimaru@ghu-paris.fr
• Phone: +33145658798

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls

  This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.

  Recruiting at 10 sites Fondation FondaMental · Besançon and 16 other locations · NCT07881016

• Mapping complex cognitive problems across psychiatric and neurological conditions

  This project will test a set of cognitive tests and optional brain recordings in adults with psychiatric or neurological disorders and healthy volunteers to map high-level thinking problems and how they change over time.

  Recruiting at 2 sites Centre Hospitalier St Anne · Paris and 2 other locations · NCT07295652

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• Affective Cognitive Training for mood disorders and their close relatives

  A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.

  Recruiting Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Frederiksberg, Capital Region of Denmark · NCT07920302

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.